An observational study in Alzheimer Disease, sponsored by Central Hospital, Nancy, France. Recruiting at 3 sites in France. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-06-25.
Sponsored by Central Hospital, Nancy, France · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Alzheimer Disease by Central Hospital, Nancy, France — 9 open to participants now, 9 under way, none of them phase 3. Alzheimer Disease · Central Hospital, Nancy, France.
Among the 17 studies in Alzheimer Disease by Central Hospital, Nancy, France, this one is one of 2 that started in 2026, is one of 8 observational ones, and was the 16th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →9 of the 17 studies in Alzheimer Disease by Central Hospital, Nancy, France are open now, in 1 country. Recruiting first, the newest first:
Central Hospital, Nancy, France · Sites in France
Ages 18–80
Central Hospital, Nancy, France · Sites in France
Central Hospital, Nancy, France · Sites in France
Central Hospital, Nancy, France · Sites in France
Ages 25–65 · Healthy volunteers
Central Hospital, Nancy, France · Sites in France
Ages 60+
By country, each count listing its studies:
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 40 is below the median of 200 across 817 observational studies indexed under Alzheimer Disease.
Median enrollment 77 across the 9 interventional studies, 65 across the 8 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Central Hospital, Nancy, France is the lead sponsor of 801 studies on the registry; 188 are open to participants now.
2 of the studies in Alzheimer Disease by Central Hospital, Nancy, France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07947446Central Hospital, Nancy, FranceCHUCOLATE: Current Knowledge and Prevalence of LATE-NC in Geriatric Memory Clinics at a Memory Center in Lorraine | 2026-12-31 |
| NCT06825663Central Hospital, Nancy, FranceMarker of Brain Insulin Resistance in AD Prognosis | 2027-09-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies in Alzheimer Disease by Central Hospital, Nancy, France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Reducing injected dose and/or acquisition time in amyloid PET imaging would improve comfort, radiation safety and cost-effectiveness in diagnosis and follow-up of patients. This study evaluates the impact of a deep learning-based noise reduction algorithm on visual analysis and Centiloid quantification when simulating reduced injected doses of [18F]flutemetamol.
Patients with objective cognitive impairment, referred to our department for a cerebral [¹⁸F]flutemetamol positron emission tomography scan between January 1, 2023 and July 1, 2025, will be included
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Evaluate the impact of a deep-learning noise reduction algorithm on visual analysis and centiloid quantification when simulating reduced injected doses of 18F-flutemetamol.
Visual analysis of the cerebral \[¹⁸F\]flutemetamol PET images will be performed by two nuclear medicine specialists in a blinded manner, with a third reader acting as an arbitrator in case of disagreement, according to routine diagnostic criteria.
Time frame: Day one
Started May 2026 (actual). Primary completion is estimated for Nov 2026, 6 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Hospital, Nancy, France →